A new proteomics technique, termed ubiquitin clipping, has been developed to further understanding of changes that control protein function and their role in healthy and disease states.
Browsing: MS (LC–MS/MS, HRMS, IMS)
In this interview, Ils Pijpers (Janssen R&D) discusses the challenges faced with sample preparation and method validation when using high-resolution mass spectrometry.
Discover more about a possible new avenue, free of ion-pairing, for general application in oligonucleotide quantitative LC–MS discovered by researchers in this methodology from Bioanalysis.
In this research article from Bioanalysis the authors discuss the quantitation of larger biotherapeutic proteins such as antibodies and antibody–drug conjugates compared with small molecules by LC–HRMS.
A multiplex HRMS assay for quantifying selected human plasma bile acids as candidate OATP biomarkers
This preliminary communication from Bioanalysis discusses the application of selected bile acids in plasma as endogenous probes for assessing drug–drug interactions involving hepatic drug transporters such as the organic anion-transporting polypeptides.
Development of two complementary LC–HRMS methods for analyzing sotatercept in dried blood spots for doping controls
In this research article from Bioanalysis the authors discuss the role of alternative matrices such as dried blood spots in sports drug testing, and the advantages these methods have over conventional matrices.
Hear more about the recent mass spectrometry product launches from SCIEX announced at ASMS 2019, including the new Acoustic Ejection Mass Spectrometry technology, in this interview with Neil Walsh (SCIEX; MA, USA).
In this conference report we discuss our highlights from the 67th American Society for Mass Spectrometry (ASMS; GA, USA; 2–6 June).
An isobaric labeling technique has been developed to amplify signals for comprehensive quantitative phosphoproteomic characterization of small cells populations.
2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 – PK, PD & ADA assays by hybrid LBA/LCMS & regulatory agencies’ inputs on bioanalysis, biomarkers and immunogenicity)
This part of the 2018 White Paper published in Bioanalysis focuses on the recommendations for PK, PD and ADA assays by hybrid LBA/LCMS and regulatory agencies’ input.